GENFLEET-B (02595) saw its shares rise more than 11%. At the time of writing, the stock was up 9.96% to HK$27.6, with a turnover of HK$40.0633 million. On the news front, on March 9, GENFLEET-B announced that, according to separate notices from the Shanghai Stock Exchange and the Shenzhen Stock Exchange, the company will be included in the list of investable securities for the Southbound Stock Connect program (Shanghai-Hong Kong Connect and Shenzhen-Hong Kong Connect) starting March 9, 2026. Furthermore, beginning March 9, 2026, the company will also be included by Hang Seng Indexes Company Limited as a constituent in several Hang Seng Index series, including the Hang Seng Composite Index, the Hang Seng Stock Connect Hong Kong Index, and the Hang Seng Innovative Medicines Index. Recently, GENFLEET-B announced that its drug candidate GFH375 has received Breakthrough Therapy Designation in China for the treatment of non-small cell lung cancer, marking the country's first such designation for a KRAS G12D inhibitor. Notably, preliminary research data for GFH375 in treating KRAS G12D-mutated solid tumors and NSCLC were previously featured in a Late-Breaking Abstract and an on-site oral presentation at the 2025 American Society of Clinical Oncology Annual Meeting and the World Conference on Lung Cancer. The latest research results for GFH375 in treating NSCLC patients are expected to be released at an international academic conference this year.